Today's digest is bookended by two major conferences: ESCMID Global 2026 opens in Munich with 18,000 attendees focused on antimicrobial resistance, while AACR 2026 in San Diego enters its first full session day with peptide-based oncology taking center stage. The most provocative story comes from STAT News, where GLP-1 pioneers Richard DiMarchi and Matthias Tschöp — the very scientists whose work enabled Zepbound and related drugs — now argue the field should drop GLP-1 as a target entirely, publishing data suggesting GIP/glucagon-only agonists could match GLP-1 weight loss without the tolerability issues. Circle Pharma's macrocyclic peptide cyclin A/B RxL inhibitor debuts in a coveted Chemistry-to-the-Clinic session Saturday, while Oncopeptides unveils preclinical data on an affibody-derived NK-cell engager and Longhorn Vaccines presents DRG5-BD11, a bispecific IgM antibody targeting bacterial peptidoglycan. On the consumer side, Scientific American publishes a deep dive on the wellness peptide craze, and PharmaTher files a provisional patent for microneedle delivery of BPC-157, GHK-Cu, TB-500, and KPV — positioning itself for the July PCAC reclassification. A new Omada Health study demonstrates that structured behavioral programs can double the fat loss of GLP-1 therapy while preserving muscle — a direct counter to the muscle-loss concerns that have dominated recent coverage.